{"ok":true,"nota":{"id":"bfb4c472ada92472","slug":"frenar-la-fibrinolisis-podria-salvar-vidas-en-sepsis-segun-un-modelo-c-bfb4c4","titulo":"Frenar la fibrinólisis podría salvar vidas en sepsis, según un modelo con 188 pacientes de terapia","resumen":"Analizaron a 188 adultos internados con sepsis en terapia intensiva y midieron la capacidad de sus coágulos para disolverse. Después calcularon cuántas muertes podrían evitarse si esa capacidad se restaurara.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Coupland, L., Self, M., Suryana, E., Law, R., Crispin, P., Keragala, C., Frost, S., Rabbolini, D., Moore, P., Medcalf, R","url":"https://www.medrxiv.org/content/10.64898/2026.10.24.26366402v1?rss=1","imagen":"/hoy/portada/bfb4c472ada92472","tema":"salud","subtemas":["sepsis","coagulación","terapia intensiva","fibrinólisis","mortalidad"],"entidades":["Reino Unido"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-26T00:00:00.000Z","indexTs":"2026-10-26T23:22:05.517Z","hash":"9fe4886d44426f1c5d21a03a902b886caa53b0a40dd7256822740f6b5aecd55e","tsa":{"time":"Oct 26 23:22:58 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hasta ahora los ensayos sobre coagulopatía en sepsis apuntaban a frenar la coagulación, no a destrabar la disolución de coágulos. Según el modelo, recuperar esa capacidad podría reducir la mortalidad, lo que orienta el diseño de los próximos tratamientos. Para un paciente o su familia, esto significa que la investigación empieza a mirar otro mecanismo que hoy puede estar detrás del fallo de órganos, aunque todavía falta comprobarlo en personas.","quienFirma":"Universidad de Newcastle","confianza":"preprint","consulta":null},"sello":{"hash":"9fe4886d44426f1c5d21a03a902b886caa53b0a40dd7256822740f6b5aecd55e","sello":"851b7f4e24c89584fd08bc05dec221ef0fe3d781cf6e651580e94655dc9abd53","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6587531,"aleatorio":"fe6a0d1e32f33530ee3865ce898a933a679d836c030556cafcf9f7f9e03e9c1f","tiempo":"2026-10-26T23:22:30.000Z"},"nist":{"cadena":2,"pulso":2000959,"salida":"38EFC3652F96D1340187DD7D5B32A840F878CD33000D34F2E88A92400DF1FC86B990B57549F5A1FBF1EAABF05D417E628C2ED1C646A08A636235AA53F1954B2D","tiempo":"2026-10-26T23:22:00.000Z"},"noAntes":"2026-10-26T23:22:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 26 23:22:58 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Modelled mortality benefits of reducing fibrinolysis resistance in sepsis: integrating observational and ex vivo data","descripcion":"Background. Suppressed fibrinolysis (fibrinolysis resistance) is increasingly recognised as a driver of organ failure in sepsis, yet trials in sepsis-induced coagulopathy have largely targeted coagulation rather than fibrinolysis. This study combined an observational ICU cohort with nested analyses of plasma fibrinolysis proteins and ex vivo reversibility, modelling the potential mortality reduction from restoring fibrinolytic capacity to inform trial design. Methods. In 188 adults admitted to ICU with sepsis, repeated tissue plasminogen activator (tPA)-enhanced viscoelastometric testing quantified fibrinolysis resistance as the fibrin adjusted lysis time (TPA-LT/FIBA10) and as ordinal Grade","pubDate":"2026-10-26","url":"https://www.medrxiv.org/content/10.64898/2026.10.24.26366402v1?rss=1"},"indexado":"2026-10-26T23:22:05.517Z"}}